BioCentury | Feb 19, 2021
Finance

Feb. 19 Quick Takes: New Horizon triples in Hong Kong IPO; plus Alta, Hangzhou Sciwind, Molecular Templates, BeiGene-BITT and Charles River-Cognate

...for Hangzhou SciwindHangzhou Sciwind Biosciences Co. Ltd. closed a $37 million series B round, with LYFE Capital...
BioCentury | Jan 5, 2021
Finance

Immuneering, Terns, Ikena raise crossover rounds as IPO queue stands to grow again

...Price; affiliates of BlackRock; Perceptive Advisors; and LYFE Capital.Participants...
BioCentury | Dec 2, 2020
Finance

Canbridge broadens investor syndicate with $43M series E

...E round included Hudson Bay Capital Management, RA Capital, Hangzhou Tigermed Consulting Co. Ltd (SZSE:300347) and Lyfe Capital.TARGETSHER2...
BioCentury | Oct 8, 2020
Product Development

Mapping opportunities for China’s early cancer detection boom

...population scale.” Mao Mao, SeekIn The market potential for pre-symptomatic screening looms especially large in China. Lyfe Capital’s...
...projects China’s early cancer screening market will be $25-30 billion in the next ten years. Lyfe Capital...
...Johnson & Johnson (NYSE:JNJ) to track over 3,000 patients with pulmonary nodules identified by CT scans. Lyfe Capital’s...
BioCentury | Oct 16, 2019
Financial News

China-heavy syndicate backs $80M series B for antiviral play Ansun

...fellow existing Chinese investors Yuanming Capital, Lilly Asia Ventures, Matrix Partners China, 3E Bioventures and LYFE Capital...
BioCentury | Aug 28, 2019
Financial News

HiFiBiO’s $67M series C attracts Kite, international syndicate

...in a couple years. Existing investors Sequoia Capital China, VI Ventures, Legend Star Capital and LYFE Capital...
BioCentury | Feb 15, 2019
Financial News

China’s Burning Rock, Sciwind close venture rounds

...$29.5 million) in a series A round. GIC led Burning Rock’s financing, with participation by Lyfe Capital...
BioCentury | Feb 15, 2019
Financial News

China’s Burning Rock, Sciwind close venture rounds

...$29.5 million) in a series A round. GIC led Burning Rock’s financing, with participation by Lyfe Capital...
BioCentury | May 18, 2018
Finance

Ansun’s China ambitions

...Fund and Lilly Asia Ventures led the round, with participation from fellow new Chinese investors Lyfe Capital...
...of operations. “China demonstrates a strong market potential for Ansun in the future.” James Zhao, Lyfe Capital...
...led by Sequoia China and Lyfe. Jennie Walters, Staff Writer Fludase, ParaDase (DAS181) Ansun BioPharma Inc. FOG Pharmaceuticals Inc. HiFiBiO Therapeutics Lyfe Capital...
BioCentury | May 18, 2018
Financial News

Ansun raises $85M series A, plans Phase III for anti-viral

...series A round led by Sinopharm Healthcare Fund and Lilly Asia Ventures. New investors included Lyfe Capital...
Items per page:
1 - 10 of 18
BioCentury | Feb 19, 2021
Finance

Feb. 19 Quick Takes: New Horizon triples in Hong Kong IPO; plus Alta, Hangzhou Sciwind, Molecular Templates, BeiGene-BITT and Charles River-Cognate

...for Hangzhou SciwindHangzhou Sciwind Biosciences Co. Ltd. closed a $37 million series B round, with LYFE Capital...
BioCentury | Jan 5, 2021
Finance

Immuneering, Terns, Ikena raise crossover rounds as IPO queue stands to grow again

...Price; affiliates of BlackRock; Perceptive Advisors; and LYFE Capital.Participants...
BioCentury | Dec 2, 2020
Finance

Canbridge broadens investor syndicate with $43M series E

...E round included Hudson Bay Capital Management, RA Capital, Hangzhou Tigermed Consulting Co. Ltd (SZSE:300347) and Lyfe Capital.TARGETSHER2...
BioCentury | Oct 8, 2020
Product Development

Mapping opportunities for China’s early cancer detection boom

...population scale.” Mao Mao, SeekIn The market potential for pre-symptomatic screening looms especially large in China. Lyfe Capital’s...
...projects China’s early cancer screening market will be $25-30 billion in the next ten years. Lyfe Capital...
...Johnson & Johnson (NYSE:JNJ) to track over 3,000 patients with pulmonary nodules identified by CT scans. Lyfe Capital’s...
BioCentury | Oct 16, 2019
Financial News

China-heavy syndicate backs $80M series B for antiviral play Ansun

...fellow existing Chinese investors Yuanming Capital, Lilly Asia Ventures, Matrix Partners China, 3E Bioventures and LYFE Capital...
BioCentury | Aug 28, 2019
Financial News

HiFiBiO’s $67M series C attracts Kite, international syndicate

...in a couple years. Existing investors Sequoia Capital China, VI Ventures, Legend Star Capital and LYFE Capital...
BioCentury | Feb 15, 2019
Financial News

China’s Burning Rock, Sciwind close venture rounds

...$29.5 million) in a series A round. GIC led Burning Rock’s financing, with participation by Lyfe Capital...
BioCentury | Feb 15, 2019
Financial News

China’s Burning Rock, Sciwind close venture rounds

...$29.5 million) in a series A round. GIC led Burning Rock’s financing, with participation by Lyfe Capital...
BioCentury | May 18, 2018
Finance

Ansun’s China ambitions

...Fund and Lilly Asia Ventures led the round, with participation from fellow new Chinese investors Lyfe Capital...
...of operations. “China demonstrates a strong market potential for Ansun in the future.” James Zhao, Lyfe Capital...
...led by Sequoia China and Lyfe. Jennie Walters, Staff Writer Fludase, ParaDase (DAS181) Ansun BioPharma Inc. FOG Pharmaceuticals Inc. HiFiBiO Therapeutics Lyfe Capital...
BioCentury | May 18, 2018
Financial News

Ansun raises $85M series A, plans Phase III for anti-viral

...series A round led by Sinopharm Healthcare Fund and Lilly Asia Ventures. New investors included Lyfe Capital...
Items per page:
1 - 10 of 18